Myositis, Inclusion Body: all 65 studies

Page 1 of 1. Open to participants first (10), then studies with results posted, then the rest; newest registration first within each.

• Imaging Assessment of Swallowing and Speech Muscles in Inclusion Body MyositisRecruitingNCT07823101
• IBM Dietary Surveillance StudyNot yet recruitingNCT07535996
• MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)RecruitingNCT07374107
• Emerging Indications for Hyperbaric Oxygen TreatmentNot yet recruitingNCT07240649Phase 4
• The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.Enrolling by invitationNCT07072676Not applicable
• Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular DisordersEnrolling by invitationNCT06605612
• Ruxolitinib Treatment in Inclusion Body MyositisRecruitingNCT06536166Phase 2
• Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body MyositisRecruitingNCT06479863Early Phase 1
• Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe DiseaseRecruitingNCT05272969
• Adult and Juvenile MyositisRecruitingNCT00017914
• A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body MyositisCompletedNCT05721573Phase 2/3Results posted
• Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension TrialTerminatedNCT04049097Phase 3Results posted
• Study of Arimoclomol in Inclusion Body Myositis (IBM)CompletedNCT02753530Phase 2Results posted
• An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203CompletedNCT02573467Phase 3Results posted
• Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body MyositisCompletedNCT02250443Phase 2/3Results posted
• Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM PatientsCompletedNCT01925209Phase 2/3Results posted
• Efficacy and Tolerability of BAF312 in Patients With PolymyositisTerminatedNCT01801917Phase 2Results posted
• Efficacy and Tolerability of BAF312 in Patients With Polymyositis and DermatomyositisTerminatedNCT01148810Phase 2Results posted
• Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle SymptomsCompletedNCT01032993Phase 2/3Results posted
• The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory MarkersCompletedNCT00805870Phase 2Results posted
• Arimoclomol in Sporadic Inclusion Body MyositisCompletedNCT00769860Phase 2/3Results posted
• The Aim of the Study is to Characterize Patients Exhibiting Muscular Atrophy and Weakness Who Require a Muscle Biopsy for Diagnosis (IBM vs Atypical MND), Through an Innovative Technique Which Enables the Evaluation of the Neuromuscular Junction Involvement in Each ConditionActive, not recruitingNCT07796776
• Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular DiseaseActive, not recruitingNCT07478172Not applicable
• Exercise as Treatment for Patients With Inclusion Body MyositisCompletedNCT06644482Not applicable
• Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body MyositisActive, not recruitingNCT06450886Phase 2/3
• Monitoring Biomarker for Detecting Change in Physical Activity and Limb Function in Inclusion Body Myositis Over TimeActive, not recruitingNCT06153108
• Effect of 8-week Supplementation With Black Chokeberry on Recovery in Highly Trained RowersCompletedNCT06133751Phase 4
• The Risk of Falls Index for Patients With Neuromuscular DisordersCompletedNCT05890833
• The Effect of Supplementation of Vitamin D3 on Inflammation Induced by 100 km Running, Iron Metabolism and ErythropoiesisCompletedNCT05880030Not applicable
• Sporadic Inclusion Body Myositis Natural History StudyActive, not recruitingNCT05046821
• Cell Therapy for IBM by Muscle Injection of ADSVFStatus unknownNCT05032131Phase 1
• Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative CellsCompletedNCT04975841Not applicable
• Musculoskeletal Nociceptive Pain in Participants With Neuromuscular DisordersCompletedNCT04907162
• Phase III Trial of Sirolimus in IBMActive, not recruitingNCT04789070Phase 3
• A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients with (IBM)CompletedNCT04659031Phase 1
• Safety and Tolerability of Phenylbutyrate in Inclusion Body MyositisCompletedNCT04421677Phase 1
• Effectiveness of Two Different Forms of Marine Oil on Indirect Markers of Muscle Damage and Soreness in Untrained MenCompletedNCT03760757Not applicable
• Influence of Aerobic Training and Weight Loss on Skeletal Muscle Inflammatory Markers and Muscle Protein Balance in Older AdultsStatus unknownNCT03743675Not applicable
• Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body MyositisWithdrawnNCT03710941Phase 2
• Establishing Muscle Impedance Parameters With Electrical Impedance MyographyCompletedNCT03633318
• Study of Pioglitazone in Sporadic Inclusion Body MyositisCompletedNCT03440034Phase 1
• Protein Supplementation and Muscle Recovery in FootballCompletedNCT03348267Not applicable
• Safety and Efficacy of a Flavonoids- and omega3s-based Compound for the Treatment of Muscular DystrophiesCompletedNCT03317171Not applicable
• Molecular Profile of the Evolution of Inclusion Body MyositisCompletedNCT03299335Not applicable
• Acceptance and Commitment Therapy for Muscle DiseaseCompletedNCT02810028Not applicable
• Pharmacoepidemiologic General Research Extension: PGRx-sIBM StudyStatus unknownNCT02735447
• Natalizumab in Inclusion Body Myositis (IBM)Status unknownNCT02483845Phase 1
• Rapamycine vs Placebo for the Treatment of Inclusion Body MyositisCompletedNCT02481453Phase 2/3
• Blood-flow Restricted Exercise in Inclusion Body MyositisCompletedNCT02317094Not applicable
• Natural History in CCFDN and IBM SyndromesCompletedNCT01902940
• Environmental Risk Factors for Myositis in Military PersonnelCompletedNCT01734369
• Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body MyositisCompletedNCT01519349Phase 1
• Diagnostic Accuracy of Whole Body Magnetic Resonance Imaging in Inflammatory MyopathiesCompletedNCT01432613Not applicable
• Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body MyositisCompletedNCT01423110Phase 2
• Investigating Genes in Patients With Polymyositis and DermatomyositisActive, not recruitingNCT01171573
• Anakinra in MyositisCompletedNCT01165008Phase 2/3
• Efficacy of a New Delivery System for Beta-hydroxy-beta-methylbutyrateCompletedNCT01150526Phase 1
• Lithium in Inclusion Body Myositis (IBM)CompletedNCT00917956
• Muscle Strength and Inflammatory Response in Patients With Inclusion Body MyositisCompletedNCT00898989
• Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body MyositisCompletedNCT00802815Early Phase 1
• Treatment With TNF Blockade, Infliximab, in Patients With MyositisCompletedNCT00443222Phase 2/3
• Alemtuzumab to Treat Sporadic Inclusion Body MyositisCompletedNCT00079768Phase 2
• Immune Abnormalities in Sporadic Inclusion Body MyositisCompletedNCT00030212
• Study and Treatment of Inflammatory Muscle DiseasesCompletedNCT00001265
• Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory MyopathiesCompletedNCT00001261Phase 2

← Myositis, Inclusion Body overview